Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Elicera Therapeutics AB has appointed DNB Carnegie Investment Bank AB (publ) as its Certified Adviser effective December 1, 2025 and as Liquidity Provider effective January 22, 2026, replacing Mangold Fondkommission AB which will continue in the roles until those dates. A prior press release incorrectly listed the liquidity provider change as February 2, 2026 and has been corrected; contact and disclosure details were provided. Elicera is a Nasdaq First North Growth Market–listed biotech developing the iTANK platform for CAR T-cell therapies and holds related patented technology; the announcement is an administrative market-advisory change rather than an operational or financial update.

Analysis

Market structure: The advisor/liquidity-provider switch to DNB Carnegie (Certified Adviser from Dec 1, 2025; liquidity provision from Jan 22, 2026) is a technical corporate-governance change that primarily benefits Elicera shareholders via likely tighter spreads and higher intraday depth; DNB Carnegie and buy-side desks focused on Nordic small-cap biotech stand to gain fee flow and client access. Competitive dynamics for CAR‑T developers are unchanged clinically, but improved liquidity and a higher-profile adviser raises odds of inbound licensing or a secondary raise, shifting relative investor attention from illiquid peers to Elicera over the next 1–3 months. Supply/demand: expect short-term increased sell-side capacity for blocks (supply) but also increased institutional eligibility (demand) — net effect likely a 10–30% reduction in quoted spreads over 30–90 days if average daily volume (ADV) rises >50%. Cross-asset impact is negligible beyond SEK flows; no material bond/commodity impact, but options will remain thinly traded until ADV expands materially.

Risk assessment: Tail risks include a negative clinical readout or IP/regulatory challenge (low-probability, high-impact) and a pre-announced equity raise that dilutes >15–25% of market cap; model stress scenarios for dilution of SEK 100–300m (medium-tier Nordic raise) which could knock 20–40% off the price. Immediate (days) effects: muted; short-term (weeks–months): liquidity transition and possible capital markets activity; long-term (quarters–years): clinical milestones and licensing convert to binary value drivers. Hidden dependencies: adviser change often precedes fundraising or M&A roadshows — treat any DNB-led investor meeting as a material catalyst within 30–90 days. Catalysts to watch: clinical updates, licensing announcements, and any prospectus filing (likely within 60 days post-liquidity change).

Trade implications: Direct play — establish a tactical 1–2% long position in Elicera (Nasdaq First North listed) starting Dec 1, 2025, size to 3% if ADV increases >50% or spread narrows >20% within 30 days; trim 50% if a primary raise >SEK 150m is announced. Pair trade — long Elicera vs short IBB (Ticker: IBB) sized 0.5–0.75% NAV to hedge sector beta during potential re-rating; rebalance monthly. Options — avoid illiquid short-dated options; consider buying deep-dated LEAP puts (6–12 month) for 0.25% NAV as tail-risk hedge if financing risk rises. Sector rotation — prefer Nordic/small-cap biotech over broad biotech (IBB/XLV) for 1–3 month alpha capture, reverting to fundamentals-driven allocation post-clinical readouts.

Contrarian angles: Consensus treats this as a neutral technical change; miss is underestimating probability of near-term capital markets activity — historically, Swedish small-cap advisers swaps precede 60–80% of raises or block M&A within 90 days. The market may underprice the upside from a licensing deal; a modest licensing announcement can drive 30–100% re-rating versus standalone clinical progress. Unintended consequence: improved liquidity could enable larger selling by insiders or early investors — set stop-loss rules (15% below cost) and size positions assuming up to 25% post-raise dilution.

Key Decisions for Investors

• Establish a tactical 1–2% NAV long position in Elicera (Nasdaq First North) starting Dec 1, 2025; increase to 3% if ADV rises by >50% or bid-ask spread narrows by >20% within 30 days.
• Implement a hedged pair trade: long Elicera 1% NAV, short IBB 0.5–0.75% NAV to neutralize broad biotech beta while capturing idiosyncratic re-rate potential over 1–3 months.
• If Elicera announces a primary equity raise >SEK 150m or prospectus filing within 60 days of Jan 22, 2026, reduce net exposure by 50% immediately and reassess post-offer; assume dilution of 15–30% in downside scenarios.
• Purchase 6–12 month LEAP put protection equal to ~0.25% NAV if financing risk rises (e.g., roadshow or filing) to cap tail loss; avoid short-dated options due to illiquidity and wide spreads.